Cormorant Asset Management’s Cellectar Biosciences CLRB Stock Holding History

Cormorant Asset Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-18	Closed	-$87K	–	56
2017 Q2	$87K	Hold	18	–	–	0.01%	68
2017 Q1	$122K	Hold	18	–	–	0.02%	74
2016 Q4	$65K	Hold	18	–	–	0.01%	76
2016 Q3	$145K	Hold	18	–	–	0.02%	82
2016 Q2	$185K	Hold	18	–	–	0.03%	83
2016 Q1	$180K	Hold	18	–	–	0.03%	83
2015 Q4	$390K	Hold	18	–	–	0.05%	78
2015 Q3	$1.04M	Hold	18	–	–	0.17%	73
2015 Q2	$1.53M	Hold	18	–	–	0.2%	66
2015 Q1	$1.65M	Hold	18	–	–	0.25%	58
2014 Q4	$1.64M	Hold	18	–	–	0.25%	55
2014 Q3	$1.18M	Buy	+18	New	+$1.55M	0.24%	56

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIM

Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

WAM

Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cormorant Asset Management's CLRB Position: Q3 2017 in Review

Cormorant Asset Management sold out of Cellectar Biosciences (CLRB) in Q3 2017, closing a stake of 18 shares — an estimated $87K sold.

Cormorant Asset Management first reported a position in CLRB in Q3 2014 and held it in 12 quarters. The position peaked at $1.65M in Q1 2015. 8 funds tracked by Wall St. Rank hold CLRB as of Q3 2017.

Cormorant Asset Management reported no remaining Cellectar Biosciences position as of Q3 2017 after selling out during the quarter.
Cormorant Asset Management sold 18 Cellectar Biosciences shares in Q3 2017, an estimated $87K.
Cormorant Asset Management first reported a position in Cellectar Biosciences in Q3 2014 and held it in 12 quarters.
Cormorant Asset Management's Cellectar Biosciences position peaked at $1.65M in Q1 2015.
8 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.